Cathay Biotech Inc.

SHSE:688065 Stock Report

Market Cap: CN¥24.4b

Cathay Biotech Past Earnings Performance

Past criteria checks 3/6

Cathay Biotech's earnings have been declining at an average annual rate of -4%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 9.4% per year. Cathay Biotech's return on equity is 2.6%, and it has net margins of 14.4%.

Key information

-4.0%

Earnings growth rate

-6.6%

EPS growth rate

Chemicals Industry Growth12.1%
Revenue growth rate9.4%
Return on equity2.6%
Net Margin14.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality Issues

Nov 07
Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality Issues

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

May 06
We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

Recent updates

Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality Issues

Nov 07
Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality Issues

What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Oct 22
What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate Capital

Oct 20
Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate Capital

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Sep 29
Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding Up

Sep 07
Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding Up

There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Jun 19
There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

May 28
Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

May 07
What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

May 06
We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

Revenue & Expenses Breakdown

How Cathay Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:688065 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,764398238232
30 Jun 242,528372227203
31 Mar 242,293414198184
31 Dec 232,114367215189
30 Sep 232,169381235179
30 Jun 232,183459256187
31 Mar 232,285436270199
31 Dec 222,441553239188
30 Sep 222,447605207184
30 Jun 222,517619188164
31 Mar 222,538628182145
31 Dec 212,363595181134
30 Sep 212,099612143118
30 Jun 211,83956414799
31 Mar 211,57948114497
31 Dec 201,49745814684
30 Sep 201,48242818170
30 Jun 201,60143220341
31 Mar 201,722475258105
31 Dec 191,91647921290
31 Dec 181,75746618586
31 Dec 171,36333313165
31 Dec 1692914510538

Quality Earnings: 688065 has high quality earnings.

Growing Profit Margin: 688065's current net profit margins (14.4%) are lower than last year (17.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 688065's earnings have declined by 4% per year over the past 5 years.

Accelerating Growth: 688065's earnings growth over the past year (4.4%) exceeds its 5-year average (-4% per year).

Earnings vs Industry: 688065 earnings growth over the past year (4.4%) exceeded the Chemicals industry -4.7%.

Return on Equity

High ROE: 688065's Return on Equity (2.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cathay Biotech Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Junjun ZhuHaitong International Research Limited